Published • loading... • Updated
Year in Review: Alzheimer's Disease
FDA approved the first blood-based tests for Alzheimer's biomarkers and reported multi-year clinical benefits for anti-amyloid drugs lecanemab and donanemab in 2025.
Summary by MedPage Today
4 Articles
4 Articles
How the cheese-noodle principle could help counter Alzheimer's
Researchers at the Paul Scherrer Institute PSI have clarified how spermine—a small molecule that regulates many processes in the body's cells—can guard against diseases such as Alzheimer's and Parkinson's: It renders certain proteins harmless by acting a bit like cheese on noodles, making them clump together. This discovery could help combat such diseases. The study has now been published in the journal Nature Communications.
Year in Review: Alzheimer's Disease
(MedPage Today) -- News about Alzheimer's rose to the forefront in 2025, as the FDA approved the first diagnostic blood test and drugmakers reported 3-year outcomes for both anti-amyloid drugs, lecanemab (Leqembi) and donanemab (Kisunla). The...
·New York, United States
Read Full ArticleCoverage Details
Total News Sources4
Leaning Left0Leaning Right1Center2Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
C 67%
R 33%
Factuality
To view factuality data please Upgrade to Premium


